Nanjing Pharmaceutical Valuation Multiples

Nanjing Pharmaceutical is valued at $964M as of September 2026, a 0.3x revenue multiple. In the last fiscal year, Nanjing Pharmaceutical revenue was $8.2B and Nanjing Pharmaceutical EBITDA was $257M.

Nanjing Pharmaceutical Overview

About Nanjing Pharmaceutical

Nanjing Pharmaceutical is a Chinese pharmaceutical distribution and retail group whose operating history dates to 1951. Listed on the Shanghai Stock Exchange since 1996, it supplies medicines and healthcare products to medical institutions and serves consumers through pharmacy chains. Its core business combines pharmaceutical wholesaling with retail pharmacy sales, supported by regional warehousing, delivery and supply-chain services. The company also distributes medical devices and provides specialized pharmacy services, including preparation and delivery of traditional Chinese medicine products. Its corporate overview describes a network covering Jiangsu, Anhui, Fujian and Hubei, together with operations in Kunming and other regional markets. For 2025, it reported approximately 500 retail pharmacies and 49 logistics centers, illustrating the physical distribution infrastructure through which it connects suppliers, healthcare providers and patients.


Founded

1951

HQ

China

Employees

7.2K

Website

njyy.com

Financials (Last FY)

Revenue: $8.2B
EBITDA: $257M

EV

$2.1B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Nanjing Pharmaceutical Financials

Nanjing Pharmaceutical reported last fiscal year revenue of $8.2B and EBITDA of $257M.

In the same fiscal year, Nanjing Pharmaceutical generated $505M in gross profit, $257M in EBITDA, and $93M in net income.


Nanjing Pharmaceutical P&L

In the most recent fiscal year, Nanjing Pharmaceutical reported revenue of $8.2B and EBITDA of $257M.

Nanjing Pharmaceutical is profitable as of last fiscal year, with gross margin of 6%, EBITDA margin of 3%, and net margin of 1%.

See analyst estimates for Nanjing Pharmaceutical
Last FY2025202620272028
Revenue$8.2B$8.2B
Gross Profit$505M$505M
Gross Margin6%6%
EBITDA$257M$257M
EBITDA Margin3%3%
EBIT Margin3%3%
Net Profit$93M$93M
Net Margin1%1%
Net Debt$387M-

Financial data powered by Morningstar, Inc.

Nanjing Pharmaceutical Stock Performance

Nanjing Pharmaceutical has current market cap of $964M, and enterprise value of $2.1B.

Market Cap Evolution


Nanjing Pharmaceutical's stock price is $0.74.

Nanjing Pharmaceutical has an EPS (earnings per share) of $0.07.

See more trading valuation data for Nanjing Pharmaceutical
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$2.1B$964M0.3%---$0.07

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Nanjing Pharmaceutical Valuation Multiples

Nanjing Pharmaceutical trades at 0.3x EV/Revenue multiple, and 8.2x EV/EBITDA.

See NTM and 2027E valuation multiples for Nanjing Pharmaceutical

Nanjing Pharmaceutical Financial Valuation Multiples

As of September 30, 2026, Nanjing Pharmaceutical has market cap of $964M and EV of $2.1B.

Nanjing Pharmaceutical has a P/E ratio of 10.3x.

Last FY2025202620272028
EV/Revenue0.3x0.3x
EV/EBITDA8.2x8.2x
EV/EBIT9.3x9.3x
EV/Gross Profit4.2x4.2x
P/E10.3x10.3x
EV/FCF(88.9x)(88.9x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Nanjing Pharmaceutical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Nanjing Pharmaceutical Margins & Growth Rates

In the most recent fiscal year, Nanjing Pharmaceutical reported gross margin of 6%, EBITDA margin of 3%, and net margin of 1%.

See estimated margins and future growth rates for Nanjing Pharmaceutical

Nanjing Pharmaceutical Margins

Last FY2025202720282029
Gross Margin6%6%
EBITDA Margin3%3%
EBIT Margin3%3%
Net Margin1%1%
FCF Margin(0%)(0%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Nanjing Pharmaceutical Operational KPIs

Nanjing Pharmaceutical's revenue per employee in the last FY averaged $1.1M, while opex per employee averaged $0.0M for the same period.

Access forward-looking KPIs for Nanjing Pharmaceutical
Last FY2025202620272028
Revenue per Employee$1.1M-
Opex per Employee$0.0M-
S&M Expenses to Revenue1%1%
G&A Expenses to Revenue0%0%
R&D Expenses to Revenue0%0%
Opex to Revenue3%3%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Nanjing Pharmaceutical Competitors

Nanjing Pharmaceutical competitors include Quest Holdings, Yixintang Pharmaceutical, Almunajem Foods, Apotea, Anhui Huaren Health, Hagar, Shu Yu Civilian Pharmacy, Chang Wah Electromaterials, Neuca and Aldawaa Medical Services.

Most Nanjing Pharmaceutical public comparables operate across Wholesale Distribution and Pharmacies.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Quest Holdings$1.7B$111M0.6x0.6x8.7x8.5x
Yixintang Pharmaceutical$2.6B$264M0.3x0.3x3.0x6.0x
Almunajem Foods$891M$65M1.2x1.2x16.1x18.3x
Apotea$723M$46M1.3x1.2x20.1x16.2x
Anhui Huaren Health$818M$97M1.2x-9.9x-
Hagar$1.6B$157M0.9x-9.1x-
Shu Yu Civilian Pharmacy$1.5B$105M0.7x0.8x10.8x11.8x
Chang Wah Electromaterials$608M$79M1.5x-11.3x-

This data is available for Pro users. Sign up to see all Nanjing Pharmaceutical competitors and their valuation data.

Start Free Trial

Nanjing Pharmaceutical VC Funding History

Before going public, Nanjing Pharmaceutical raised $89M in total equity funding, across 1 round.


Nanjing Pharmaceutical Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Sep-12Strategic investmentAlliance Boots$89M-Alliance Boots announced on September 16, 2012 that it would acquire a 12% stake in Nanjing Pharmaceutical Company Limited through a private placement. The strategic investment carried an announced consideration of RMB560 million, also described as approximately GBP56 million in the buyer’s release. Alliance Boots expected to become the listed pharmaceutical wholesaler’s second-largest shareholder and obtain representation on its board and in operational management. The transaction was subject to Chinese regulatory approvals, which prolonged the timetable beyond the original announcement. The buyer subsequently announced final regulatory approval on September 29, 2014 and completion on December 4, 2014. This is one equity investment, with the closing treated as completion of the earlier announced transaction. It expanded the KKR-backed platform’s exposure to Chinese pharmaceutical distribution alongside its existing Guangzhou venture. The reviewed announcement did not disclose transaction-specific revenue or EBITDA for Nanjing Pharmaceutical.

Acquisitions by Nanjing Pharmaceutical

Nanjing Pharmaceutical has acquired 1 company to date.

Last acquisition by Nanjing Pharmaceutical was on December 20th 2022. Nanjing Pharmaceutical acquired Suzhou Tianqing Xingwei Pharmaceutical for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by Nanjing Pharmaceutical

Suzhou Tianqing Xingwei Pharmaceutical
Description
Suzhou Tianqing Xingwei Pharmaceutical is a research and development firm focused on liver disease treatments. The company develops innovative drugs targeting hepatitis and related conditions, conducting clinical trials and securing approvals from China's National Medical Products Administration. Suzhou-based, it collaborates with hospitals across Jiangsu province for patient data and testing.
HQ CountryChina
HQ City
Suzhou
Deal Date20 Dec 2022
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Nanjing Pharmaceutical acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by Nanjing Pharmaceutical

Nanjing Pharmaceutical has invested in 1 company to date.

Latest investment by Nanjing Pharmaceutical was on February 27th 2018. Nanjing Pharmaceutical invested in WANHU HEALTH in their $500K Pre-seed round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Nanjing Pharmaceutical

WANHU HEALTH
Description
WANHU HEALTH is a health services provider specializing in disease prevention and critical illness insurance for groups. It delivers risk profiling, supplementary serious illness coverage, and early screening programs to mitigate family medical costs via wanhuhealth.com.
HQ CountryChina
HQ City
Beijing
Deal Date27 Feb 2018
RoundPre-seed
Raised$500K
InvestorsNanjing Pharmaceutical
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Nanjing Pharmaceutical investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Nanjing Pharmaceutical

When was Nanjing Pharmaceutical founded?Nanjing Pharmaceutical was founded in 1951.
Where is Nanjing Pharmaceutical headquartered?Nanjing Pharmaceutical is headquartered in China.
How many employees does Nanjing Pharmaceutical have?As of today, Nanjing Pharmaceutical has over 7K employees.
Is Nanjing Pharmaceutical publicly listed?Yes, Nanjing Pharmaceutical is a public company listed on Shanghai Stock Exchange.
What is the stock symbol of Nanjing Pharmaceutical?Nanjing Pharmaceutical trades under 600713 ticker.
When did Nanjing Pharmaceutical go public?Nanjing Pharmaceutical went public in 1996.
Who are competitors of Nanjing Pharmaceutical?Nanjing Pharmaceutical main competitors include Quest Holdings, Yixintang Pharmaceutical, Almunajem Foods, Apotea, Anhui Huaren Health, Hagar, Shu Yu Civilian Pharmacy, Chang Wah Electromaterials, Neuca, Aldawaa Medical Services.
What is the current market cap of Nanjing Pharmaceutical?Nanjing Pharmaceutical's current market cap is $964M.
What is the current revenue of Nanjing Pharmaceutical?Nanjing Pharmaceutical's last fiscal year revenue is $8.2B.
What is the current EV/Revenue multiple of Nanjing Pharmaceutical?Current revenue multiple of Nanjing Pharmaceutical is 0.3x.
Is Nanjing Pharmaceutical profitable?No, Nanjing Pharmaceutical is not profitable.
How many companies Nanjing Pharmaceutical has acquired to date?As of September 2026, Nanjing Pharmaceutical has acquired 1 company.
What was the largest acquisition by Nanjing Pharmaceutical?None of the M&A deals Nanjing Pharmaceutical has completed have disclosed valuations.
What companies Nanjing Pharmaceutical acquired?Nanjing Pharmaceutical acquired Suzhou Tianqing Xingwei Pharmaceutical.
In how many companies Nanjing Pharmaceutical has invested to date?As of September 2026, Nanjing Pharmaceutical has invested in 1 company.
In what companies Nanjing Pharmaceutical invested in?Nanjing Pharmaceutical invested in WANHU HEALTH.

See public comps similar to Nanjing Pharmaceutical

Lists including Nanjing Pharmaceutical

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial